• linkedin
  • Increase Font
  • Sharebar

    Researchers unveil optimal timing of HCV therapy in transplantation


    Questions still remain regarding the timing of DAA therapy in the context of transplantation.

    “Our analysis was restricted to only the most commonly used regimen of sofosbuvir/ledipasvir in patients with genotypes 1 and 4 HCV, and therefore does not apply to patients with other genotypes, or other emerging treatment regimens,” said Lim. “Furthermore, cost assumptions were based on wholesale acquisition cost without consideration of payer discounts or anticipated decrease in real-world prices as future regimens become available.”

    Lim added that primary care physicians need to know that “oral DAA therapies for hepatitis C are simple, well-tolerated, short in duration, and curative in more than 90% of patients. Taking active steps to screen and diagnose patients early before cirrhosis remains essential in blunting the burden of HCV in the U.S.”


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow